Cargando…

Development of a novel patient-reported measure for acromegaly: the Acro-TSQ

PURPOSE: Somatostatin analogs (SSAs) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections. Patient-reported outcomes (PROs) are increasingly common as relevant outcomes in studies of acromegaly and its treatment, but th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, Maria, Fogelfeld, Leon, Gordon, Murray B., Sisco, Jill, Colwell, Hilary H., Ludlam, William H., Haviv, Asi, Mathias, Susan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842345/ https://www.ncbi.nlm.nih.gov/pubmed/31522359 http://dx.doi.org/10.1007/s11102-019-00986-4

Ejemplares similares

An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
por: Fleseriu, Maria, et al.
Publicado: (2020)

Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider
por: Geer, Eliza B., et al.
Publicado: (2019)

ACRODAT® and AcroVoice: an insight into a holistic approach to the management of acromegaly
por: Lundie, Mark, et al.
Publicado: (2019)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice
por: Geer, Eliza B., et al.
Publicado: (2020)

SUN-LB078 Biochemically Controlled Acromegaly Patients on a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice Still Remain Symptomatic: Preliminary Results from Endocrinology Health Care Professionals
por: Geer, Eliza, et al.
Publicado: (2019)

SUN-LB077 Relationship between Responses from Acromegaly Patients Treated with a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice and Their Endocrinology Health Care Professional Regarding Treatment Outcomes: Preliminary Findings
por: Geer, Eliza, et al.
Publicado: (2019)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Acromegaly Quality of Life Questionnaire (AcroQoL)
por: Badia, Xavier, et al.
Publicado: (2004)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

AcroVoice: eliciting the patients’ perspective on acromegaly disease activity
por: Jackson, Yanina, et al.
Publicado: (2019)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

Validation of Acromegaly Quality of Life Questionnaire (AcroQoL) for the Iranian population
por: Danaei, Mina, et al.
Publicado: (2022)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

Patients with Acromegaly Presenting with Colon Cancer: A Case Series
por: Gordon, Murray B., et al.
Publicado: (2016)

Correction to: Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2021)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

Towards an Earlier Diagnosis of Acromegaly and Gigantism
por: Sisco, Jill, et al.
Publicado: (2021)

Acro-osteolysis
por: Thomas, Joe, et al.
Publicado: (2019)

SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry
por: Geer, Eliza Brevoort, et al.
Publicado: (2023)

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Identifying Persons at Risk for PTSD After Trauma with TSQ in The Netherlands
por: Dekkers, A. M. M., et al.
Publicado: (2009)

MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2023)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
por: Chin, Sang Ouk, et al.
Publicado: (2015)

Improved AcroQoL scores in acromegaly after sagittal split ramus osteotomy with Le Fort I osteotomy
por: Taguchi, Tomomi, et al.
Publicado: (2021)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

Acro-cardio-facial syndrome
por: Digilio, Maria Cristina, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_deahs7odah3ihelgokg2jblabi